UPNEEQ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Upneeq, and when can generic versions of Upneeq launch?
Upneeq is a drug marketed by Rvl Pharms and is included in one NDA. There are twelve patents protecting this drug.
This drug has forty-nine patent family members in twenty-eight countries.
The generic ingredient in UPNEEQ is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Upneeq
Indicators of Generic Entry
Summary for UPNEEQ
International Patents: | 49 |
US Patents: | 12 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 69 |
Clinical Trials: | 1 |
Patent Applications: | 2,096 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in UPNEEQ? | UPNEEQ excipients list |
DailyMed Link: | UPNEEQ at DailyMed |
Recent Clinical Trials for UPNEEQ
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Miami | Phase 4 |
Pharmacology for UPNEEQ
Drug Class | Vasoconstrictor |
Physiological Effect | Increased Sympathetic Activity Vasoconstriction |
Anatomical Therapeutic Chemical (ATC) Classes for UPNEEQ
US Patents and Regulatory Information for UPNEEQ
UPNEEQ is protected by twelve US patents.
Patents protecting UPNEEQ
Compositions and methods for treating ocular disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Oxymetazoline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Oxymetazoline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for non-surgical treatment of ptosis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for treating ocular disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Oxymetazoline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for treating ocular disorders
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for non-surgical treatment of ptosis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Compositions and methods for non-surgical treatment of Ptosis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Rvl Pharms | UPNEEQ | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 212520-001 | Jul 8, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for UPNEEQ
When does loss-of-exclusivity occur for UPNEEQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 20268329
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2021022404
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 39443
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 21002918
Estimated Expiration: ⤷ Sign Up
China
Patent: 1888326
Estimated Expiration: ⤷ Sign Up
Patent: 7045596
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 21015265
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 65737
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 7831
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 41420
Estimated Expiration: ⤷ Sign Up
Patent: 20183373
Estimated Expiration: ⤷ Sign Up
Patent: 21191802
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 21013516
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 895
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 220384
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 202112272T
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 2108950
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2410503
Estimated Expiration: ⤷ Sign Up
Patent: 200128629
Estimated Expiration: ⤷ Sign Up
Patent: 220084264
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering UPNEEQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 287831 | תרכובות אוקסימטזולין ושיטות לטיפול במחלות עיניים (Oxymetazoline compositions and methods for treating ocular disorders) | ⤷ Sign Up |
Hungary | E046740 | ⤷ Sign Up | |
Australia | 2012223615 | Compositions and methods for non-surgical treatment of ptosis | ⤷ Sign Up |
Japan | 2021191802 | 眼疾患を処置するためのオキシメタゾリン組成物および方法 (OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |